Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06451042
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-05-31
Brief Title:
FET-PETMRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients FET-TREAT
Sponsor:
Sunnybrook Health Sciences Centre
Organization:
Sunnybrook Health Sciences Centre
Study Overview
Official Title:
FET-PETMRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients FET-TREAT
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FET-TREAT
Brief Summary:
Glioblastoma multiforme GBM represent the most common primary brain malignancy and prognosis remains poor The most common subtype is glioblastoma which has a 5-year survival rate of approximately 5 Despite advances in MRI techniques accurately determining total extent of tumor remains a challenge The result is incomplete treatment resulting in reduced survival or overtreatment resulting in avoidable treatment related morbidity A more accurate means of assessing tumor extent is needed to guide management to improve patient survival and quality of life
Detailed Description:
Please see trial details below
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None